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Abstract
Background: Protease activated receptors (PARs) consist of a family of four G protein-coupled
receptors. Many types of cells express several PARs, whose physiological significance is mostly
unknown.
Results:  Here, we show that non-invasive resonant waveguide grating (RWG) biosensor
differentiates signaling of endogenous protease activated receptor subtype 1 (PAR1) and 2 (PAR2)
in human epidermoid carcinoma A431 cells. The biosensor directly measures dynamic mass
redistribution (DMR) resulted from ligand-induced receptor activation in adherent cells. In A431,
both PAR1 and PAR2 agonists, but neither PAR3 nor PAR4 agonists, trigger dose-dependent Ca2+
mobilization as well as Gq-type DMR signals. Both Ca2+ flux and DMR signals display comparable
desensitization patterns upon repeated stimulation with different combinations of agonists.
However, PAR1 and PAR2 exhibit distinct kinetics of receptor re-sensitization. Furthermore, both
trypsin- and thrombin-induced Ca2+ flux signals show almost identical dependence on cell surface
cholesterol level, but their corresponding DMR signals present different sensitivities.
Conclusion: Optical biosensor provides an alternative readout for examining receptor activation
under physiologically relevant conditions, and differentiates the signaling of endogenous PAR1 and
PAR2 in A431.
Background
Protease activated receptors (PARs) comprise a family of
G protein-coupled receptors (GPCRs) which to date
include PAR1, PAR2, PAR3 and PAR4 [1-5]. Instead of being
activated through reversible ligand binding, PARs utilize a
unique proteolytic mechanism for activation [6-8]. Serine
proteases such as thrombin and trypsin site-specifically
cleave the receptor within the extracellular N-terminal
exodomain. The activating cleavage site is the residue 41–
42 (R↓SFLLRN), 36–37(R↓SLIGKV), 38–39 (K↓TFRGAP)
and 47–48 (R↓GYPGQV) for human PAR1, PAR2, PAR3
and PAR4, respectively [9]. The cleavage unmasks a new N-
terminus, which, in turn, acts as a tethered ligand
sequence. The tethered ligand domain binds intramolecu-
larly to and activates the receptor, thus initiating signal-
ing. The proteases that activate PARs include coagulation
factors (e.g. thrombin, coagulation factors VIIa and Xa),
proteases from inflammatory cells (e.g., mast cell tryptase,
neutrophil cathepsin G) and enzymes from epithelial tis-
sues (e.g., trypsins). PAR1, PAR3 and PAR4 are activated
principally by thrombin, while PAR2  is activated by
trypsin-like proteases such as mast cell tryptase and coag-
ulation Factor Xa. Synthetic PAR-activating peptides
(PAR-APs), corresponding to the first five or six amino
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acids of the tethered ligand sequences, can directly acti-
vate PARs, except for PAR3 [3,9-13]. Since these synthetic
peptides function as receptor agonists independent of
proteolysis, PAR-APs are useful for studying the physio-
logical and pathophysiological functions of PARs.
PARs are found in a large variety of normal and malignant
tissues and cells including skin, platelets, endothelial
cells, gastrointestinal tract, brain and lungs. Most cell
types express several PARs; for example, A431 cells endog-
enously express PAR1 and PAR2 [14,15]. The presence of
several PARs in a cell type makes it unclear how the cell
differentiates among these signaling. Recently, we had
developed a non-invasive and manipulation-free cell
assay technology, termed MRCAT (Mass Redistribution
Cell Assay Technology), which is centred on resonant
The Ca2+ mobilization and DMR signals mediated through endogenous PARs in A431 Figure 1
The Ca2+ mobilization and DMR signals mediated through endogenous PARs in A431. (a) The endogenous PARs 
and their corresponding agonists. Both receptors mediate Gq signaling, which proceeds through activation of the receptor, its 
coupled G protein and downstream target phospholipase C (PLC). The PLC hydrolyzes the membrane lipid phosphatidylinosi-
tol bisphosphate (PIP2), producing inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 binds to and opens a calcium chan-
nel in the endoplasmic reticulum, leading to calcium mobilization. Calcium alters many cellular processes. The interaction of 
both DAG and calcium with protein kinase C (PKC) activates PKC kinase activity, which, in turn, phosphorylates many differ-
ent protein targets including small GTPase Rho, leading to the remodeling of cytoskeletal structure. (b) The increase in intrac-
ellular Ca2+ level as a function of the concentration of different soluble PAR agonists. (c) The real-time dynamic mass 
redistribution signals induced by SFLLR-amide at different doses. The solid arrow indicates the time when SFLLR-amide is 
introduced. The DMR consists of two phases: an increase signal (termed Positive-DMR, P-DMR) and a sequential decay signal 
(termed Negative-DMR, N-DMR). (d) The amplitudes of both P-DMR and N-DMR events, calculated as indicated in (c), as a 
function of SFLLR-amide concentration.
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waveguide grating (RWG) biosensor [16]. The RWG bio-
sensor directly measures ligand-induced dynamic mass
redistribution (DMR) within the bottom portion of
adherent cells. Theoretical and numerical analysis sug-
gests that the resultant DMR signal such as the Gq-type
DMR [16] represents a novel physiological readout for cell
signaling, which consists of contributions of many cellu-
lar events downstream the ligand-induced receptor activa-
tion. The MRCAT enables the study of systems cell biology
of receptors including epidermal growth factor receptor
(EGFR) [17] and bradykinin B2 receptor [18]. Here we
applied the MRCAT to investigate the actions of several
PAR agonists, with a special emphasis on the roles of cho-
lesterol in regulating the signaling of endogenous PARs in
A431 cells.
Results
PAR1 and PAR2 transduce Gq/11 signaling in A431
To probe the signaling of endogenous PARs in A431, both
conventional Ca2+ flux assay and the MRCAT were used to
examine the cellular responses induced by several PAR
agonists. The agonists were thrombin and SFLLR-amide
(PAR1), trypsin, SLIGKV-amide and SLIGRL-amide
(PAR2), TFRGAP (PAR3), and GYPGQV (PAR4). Among
them, only PAR1 and PAR2 agonists resulted in rapid and
transient increase in intracellular Ca2+ ([Ca2+]i) as well as
Gq-type DMR signals in quiescent A431 cells (Fig. 1 and
Fig. 2a). These results were consistent with the expression
pattern and signaling of endogenous PARs in A431. A431
is known to express PAR1 and PAR2, which both mediate
classical Gq signaling [14,15].
Table 1: EC50 values of PAR agonists in A431. EC50 values were obtained using conventional Ca2+ flux assay, in comparison with those 
obtained using the MRCAT. In the case of MRCAT data, the amplitudes of both P-DMR and N-DMR events as a function of agonist 
concentration (as indicated in Fig. 1c) were used to calculate EC50.
Ligand EC50 (n = 3)
Ca2+ flux assay P-DMR N-DMR
Trypsin 45.7 ± 5.8 nM 98.0 ± 27.8 nM 102.1 ± 21.9 nM
SLIGRL-amide 2.5 ± 0.3 μM2 . 3  ±  0 . 6  μM 3.2 ± 0.8 μM
SLIGKV-amide 3.8 ± 0.4 μM6 . 1  ±  1 . 0  μM 9.1 ± 2.2 μM
Thrombin 6.0 ± 1.0 unit/ml 9.6 ± 2.0 unit/ml 11.0 ± 1.9 unit/ml
SFLLR-amide 5.0 ± 0.4 μM1 . 9  ±  0 . 1  μM 3.1 ± 0.2 μM
Correlation between the maximal Ca2+ mobilization and DMR responses induced by PAR agonists Figure 2
Correlation between the maximal Ca2+ mobilization and DMR responses induced by PAR agonists. (a) The DMR 
signals induced by PAR agonists: TFRGAP (20 μM), GYPGQV (20 μM), SLIGRL-amide (20 μM), SLIGKV-amide (20 μM), 
thrombin (40 unit/ml), SFLLR-amide (20 μM), trypsin (1024 nM), SFLLR-amide+SLIGRL-amide (each at 20 μM). (b) Comparison 
of the maximal DMR and Ca2+ mobilization responses induced by different PAR agonists. The DMR response was calculated 
using the amplitude of the P-DMR event. Since trypsin at doses greater than ~1000 nM led to significant cell detachment (ref. 
16), the DMR signal induced by trypsin at 1024 nM was used as its maximal response.
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Both Ca2+  mobilization and DMR signals were dose-
dependent and saturable to each agonist, including
trypsin or SFLLR-amide at low doses. The saturation
curves obtained seem fit well with one-site binding, based
on non-linear regression and Scatchard analysis. The EC50
values of each agonist obtained using both methods were
comparable (Table 1), suggesting that similar to conven-
tional Ca2+ signals, the ligand-induced DMR signals could
also be used as alternative readouts for examining recep-
tor activation. We previously had shown that trypsin of
high doses (>~1000 nM) led to complicated DMR signals,
due to the combination of trypsin-induced cell signaling
and cell detachment from the sensor surface [16]. Thus,
the DMR signals induced by trypsin only at low doses
were analyzed. Interestingly, SFLLR-amide at high doses
(>40 μM) led to intracellular Ca2+ level as well as DMR sig-
nal to another elevated level (Fig. 1b and 1d). A possible
explanation is that SFLLR-amide at high doses activates
both PAR1 and PAR2, consistent with the previous find-
ings done by others that SFLLR-amide has higher efficacy
to activate PAR1 than PAR2 [9]. Alternatively, beside the Gq
pathway, SFLLR-amide at high doses may also lead to the
activation of a second signaling pathway, which could fur-
ther increase both the Ca2+ mobilization and DMR sig-
nals. It has been reported that the activation of several Gi-
coupled receptors results in Ca2+ mobilization through
Gβγ subunits of Gi/o proteins [19], and a dose-dependent
switching of receptor signaling could occur for some
GPCR-ligand systems [20].
Functional interactions between PAR1 and PAR2
Since A431 expresses both PAR1 and PAR2, we were inter-
ested in the possibility of functional interactions between
the two receptors. First, we examined the maximal
responses induced by PAR agonists (Fig. 2). The maximal
[Ca2+]i  elevation induced by trypsin, SLIGRL-amide,
SLIGKV-amide, thrombin, and SFLLR-amide was found to
be 100 ± 6%, 64 ± 4%, 52 ± 6%, 48 ± 4%, and 74 ± 4%,
respectively. The maximal [Ca2+]i elevation induced by
trypsin was approximately 2 fold as high as those induced
by thrombin, SLIGKV-amide or SLIGRL-amide, whereas
SFLLR-amide at 80 μM led to an intermediate maximal
[Ca2+]i elevation. Furthermore, a mixture of SFLLR-amide
and SLIGKV-amide (both at 20 μM) resulted in an [Ca2+]i
elevation of 102 ± 5.4%. At saturating concentrations,
these agonists also led to similar DMR signals but with
different maximal amplitudes (Fig. 2a). The maximal
amplitudes of these DMR signals had an order that is
almost identical, but less pronounced, to those obtained
using Ca2+ flux measurements (Fig. 2b). It is worthy not-
ing that the PAR2-specific agonist SLIGKV-amide led to
Desensitization of A431 cells to repeated agonist stimulation  – Ca2+ mobilization Figure 4
Desensitization of A431 cells to repeated agonist 
stimulation – Ca2+ mobilization. The cells were subject 
to repeated stimulation, separated by 6 min, with various 
combinations of agonists. The agonist concentration was 40 
unit/ml, 200 nM, 20 μM, 20 μM, and 100 nM for thrombin, 
trypsin, SFLLR-amide, SLIGKV-amide, and bradykinin, respec-
tively.
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The effect of YFLLRNP-amide on the DMR signals induced by  PAR agonists Figure 3
The effect of YFLLRNP-amide on the DMR signals 
induced by PAR agonists. The cells were pre-treated with 
YFLLRNP-amide at different doses. The amplitudes of the P-
DMR events induced by each agonist (40 unit/ml thrombin, 
20 μM SFLLR-amide, or 20 μM SLIGKV-amide) were plotted 
as a function of YFLLRNP-amide concentration.
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relatively lower maximal responses, in terms of both Ca2+
mobilization and DMR signal, than another PAR2-specific
agonist SLIGRL-amide did.
Second, we examined the effect of PAR1 specific partial
agonist YFLLRNP-amide on ligand-induced cellular
responses. Results showed that YFLLRNP-amide at doses
up to 729 μM did not lead to any significant elevation of
[Ca2+]i; however, at high doses (>80 μM) it led to a small
DMR signal (data not shown). This is consistent with the
previous observations done by others that YFLLRNP-
amide can activate G12/13resulting in the cell shape
change, but not Gq-mediated Ca2+ signaling in human
platelets [21,22]. Furthermore, YFLLRNP-amide dose-
dependently attenuated the DMR signals induced by
thrombin or SFLLR-amide, but not SLIGKV-amide (Fig.
3). However, at the highest dose examined YFLLRNP-
amide almost completely blocked the thrombin-induced
DMR, but only partially attenuated the SFLLR-amide-
induced DMR.
Third, we examined the desensitization patterns of recep-
tor signaling, since either thrombin or trypsin potentially
activates several PARs. Figure 4 summarized Ca2+ mobili-
zation patterns in A431 in response to repeated stimula-
tion, separated by 6 min, with various combinations of
agonists. Pre-stimulation of A431 with trypsin completely
blocked the ability of PAR agonists (thrombin, SFLLR-
amide, SLIGKV-amide, SLIGRL-amide, or trypsin) to pro-
voke Ca2+ moblization (Fig. 4a–c, data not shown). Con-
versely, neither of PAR agonists examined had any effect
on the Ca2+ mobilization induced by bradykinin, an ago-
nist for bradykinin B2 receptor which is also expressed in
A431 [18,23] (exampled in Fig. 4d), suggesting that the
inhibition of the response to PAR agonists by the preced-
ing stimulation with trypsin is not due to any non-specific
digestion of the membrane proteins. On the other hand,
the pre-stimulation with thrombin completely inhibited
the responsiveness of cells to thrombin, only partially to
trypsin, but not to SLIGKV-amide or SLIGRL-amide. In
addition, the preceding stimulation with SFLLR-amide,
SLIGKV-amide or SLIGRL-amide all partially attenuated
the trypsin-induced Ca2+ mobilization (Fig. 4e–g; data not
shown). Conversely, SFLLR-amide still led to a significant
intracellular Ca2+ elevation (32 ± 4.3%) in the thrombin-
stimulated cells, consistent with the previous observations
Cholesterol removal impairs the agonist-induced Ca2+ mobi- lization Figure 6
Cholesterol removal impairs the agonist-induced 
Ca2+ mobilization. mβCD was used to deplete cell surface 
cholesterol. Its effect on agonist-induced Ca2+ mobilization 
was examined. The agonists were trypsin (200 nM) and 
thrombin (40 unit/ml).
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Desensitization of A431 cells to repeated agonist stimulation  – DMR signal Figure 5
Desensitization of A431 cells to repeated agonist 
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done by others that SFLLR-amide activates both PAR1 and
PAR2 [24,25].
Since the ligand-induced Gq-type DMR signals typically
proceed about 30 min to 1 hour, we were interested in the
desensitization and resensitization patterns of cells in
response to repeated stimulation, separated by ~1 hr, with
various combinations of GPCR agonists. Results showed
that the trypsin-treated cells became completely desensi-
tized to trypsin, or thrombin (Fig. 5a), only partially to
SFLLR-amide, SLIGKV-amide, or SLIGRL-amide (Fig. 5b–
c, data not shown), but not to bradykinin (Fig. 5d). On
the other hand, the preceding stimulation with thrombin,
SFLLR-amide, SLIGKV-amide or SLIGRL-amide only par-
tially attenuated the DMR signal induced by trypsin (Fig.
5e–g; data not shown), while bradykinin had no obvious
effect on the DMR signal induced by any PAR agonist (Fig.
5h, data not shown). Furthermore, SLIGKV-amide and
SLIGRL-amide led to almost identical DMR signals in cells
with or without pre-stimulation with thrombin (data not
shown). Together, these results suggest that both SFLLR-
amide and trypsin may activate both PAR1 and PAR2.
Differentiated regulation of PAR1 and PAR2 signaling
Since the physiological significance of co-expression of
two receptors in A431 is unclear, we were interested in the
possibility of differentiated regulation of PAR1 and PAR2
signaling. A common mechanism for the cell to regulate
and differentiate receptor signaling is compartmentaliza-
tion of receptors and/or their signaling components.
Amassing evidences support the hypothesis that there are
many cholesterol-rich microdomains at the cell surface
membrane, although their characteristics are still under
extensive investigations. Such microdomain is believed to
enable the sorting and segregation of receptors and their
signaling cascades, thus regulating cell signaling [26].
Methyl-β-cyclodextrin (mβCD) has been widely used to
extract cell surface choleterol primarily through effluxing
[27], thus disrupting these cholesterol-rich microdo-
mains. Thus, we examined the effect of cholesterol deple-
tion by mβCD on both Ca2+ mobilization and DMR
responses induced by thrombin and trypsin. The pre-treat-
ment of quiescent A431 cells with mβCD up to 16 mM led
to a dose-dependent suppression of Ca2+ mobilization
induced by either trypsin or thrombin (Fig. 6). Both dose-
dependent inhibition curves appeared fit well with a one-
phase decay non-linear regression, leading to an almost
identical half-concentration (C1/2 of ~1.5 mM) of mβCD.
This is consistent with the fact that mβCD results in rapid
effluxing of cell membrane cholesterol molecules; and the
amount of remain cell surface cholesterol depends on the
concentration of mβCD in solution [27]. The higher con-
centration mβCD is, the less cholesterol is retained at the
cell surface membrane. Since α-cyclodextrin (αCD) is an
inactive cyclodextrin analog and has been found to be
Cholesterol removal attenuates the agonist-induced DMR  signals Figure 7
Cholesterol removal attenuates the agonist-induced 
DMR signals. mβCD was used to deplete cell surface cho-
lesterol. Its effect on the amplitudes of the P-DMR events 
induced by (a) thrombin (40 unit/ml) or (b) trypsin (200 nM) 
was analyzed. In comparison, the effect of αCD was also 
included. (c) The DMR signals of A431 cells induced by 
A23187 without or with the pre-treatment with 5 mM 
mβCD.
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incapable of extracting cholesterol from cultured cells
[28], αCD was used as a negative control to study the reg-
ulation of PAR signaling by cholesterol. Unlike mβCD up
to 16 mM, αCD at high doses (>8 mM) resulted in detect-
able cell toxicity as well as significant amounts of cells
detached from the biosensor surface (data not shown).
Thus, only low doses of αCD were used. Results showed
that αCD up to 8 mM had little effect on both trypsin and
thrombin-induced Ca2+ mobilization responses (data not
shown).
Similarly, the mβCD pre-treatment also led to a dose-
dependent attenuation of the DMR signals induced by
thrombin or trypsin (Fig. 7). However, there is a clear dis-
tinction between the inhibition curves of trypsin- and
thrombin-induced DMR signals by mβCD. The suppres-
sion of the thrombin-induced DMR by mβCD exhibited a
dose-dependency (C1/2 of 1.2 ± 0.3 mM) similar to that
measured with Ca2+ mobilization (Fig. 7a). On the other
hand, the inhibition of the trypsin-mediated DMR by
mβCD displayed a much slower decay to increased con-
centrations of mβCD, which apparently fits well with a 2-
phase decay, leading to C1/2 of 5 ± 1 mM and 11 ± 2 mM,
respectively (Fig. 7b). This difference suggests that the
trypsin-mediated DMR signal involves more complicated
cellular mechanisms than that induced by thrombin. As
expected, αCD up to 8 mM had little effect on both ago-
nist-induced DMR responses. On the other hand, the pre-
treatment of A431 cells with mβCD at 5 mM had little
effect on the DMR signal induced by 5 μM A23187 (Fig.
The effect of preceding EGF stimulation on PAR signaling Figure 9
The effect of preceding EGF stimulation on PAR sig-
naling. (a) The Ca2+ mobilization. (b, c) The DMR signals. 
The ligands were EGF (100 nM), trypsin (100 nM), and 
thrombin (40 unit/ml). The cell responses with the pre-treat-
ment with the HBSS only were also included as control.
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7c), suggesting that the cholesterol-depleted cells are still
responsive to non-membrane elicited events. A23187 is a
Ca2+ ionophore, and is able to release stored Ca2+ from the
endoplasmic reticulum in cells. Interestingly, the A23187-
induced DMR signal somewhat mimics the PAR agonist-
induced DMR signals (Fig. 2a), suggesting that Ca2+ path-
way is part of the response pathway(s), and the PAR ago-
nist-induced DMR is largely downstream cellular events of
Ca2+ mobilization mediated through the receptor activa-
tion.
We further studied the functional recovery of PAR signal-
ing after cholesterol depletion with mβCD. This was
based on the timely recovery of cell surface cholesterol in
the mβCD-treated cells after replacing the medium con-
taining mβCD with the medium only. Results showed
that the thrombin-induced DMR signal progressively
recovered (Fig. 8), indicating that the formation of choles-
terol-assisted microdomains is dynamic and reversible,
and cholesterol concentration at the cell membranes is
important in regulating the PAR signaling.
Previously we had shown that blockage of EGFR tyrosine
kinase activity by AG1478 partially attenuated the trypsin-
induced DMR signal in A431 [16], suggesting that EGFR
transactivation may be a downstream event of trypsin-
induced response. A431 cells express large numbers of
EGF receptors [29]. AG1478 is a potent and selective
EGFR tyrosine kinase inhibitor. It is also known that cho-
lesterol removal by mβCD triggers a ligand-independent
transactivation of EGFR in A431 cells [28,30]. Thus, we
were interested the interference of EGFR activation with
PAR signaling. The preceding stimulation with EGF had
little effect on the Ca2+ mobilization induced by trypsin
(Fig. 9a) or thrombin (data not shown). However, at 100
nM EGF almost completely inhibited the N-DMR event,
but only slightly attenuated the P-DMR event in the DMR
signal induced by either trypsin (Fig. 9b) or thrombin
(Fig. 9c). However, the pre-treatment of A431 cells with
AG1478 did not counter the inhibitory effect of choles-
terol depletion on the trypsin-induced DMR signals (data
not shown). Together, these results suggest that both
trypsin and thrombin-induced signaling are sensitive to
EGFR activation.
Discussion
There is growing evidence that GPCR signaling is compli-
cated – many GPCRs including PAR2 elicit both G protein-
dependent and independent signaling events [20,31]. To
complicate this, a GPCR may exist in a collection of
microstates (i.e., conformations), and different agonists
may result in distinct active-state conformations, thus
directing the receptor-induced signals to various cellular
pathways [32,33]. Conventional cell-based assays typi-
cally measure a singular cellular response (e.g., second
messenger generation, protein interactions or trafficking).
Because of that, these assays may lead to false negatives,
due to alternative pathway a ligand may selectively acti-
vate. On the other hand, the non-invasive optical biosen-
sor used here utilizes an evanescent wave with a short
penetration depth (~200 nm) to probe ligand-induced
dynamic redistribution of cellular matter; the resultant
DMR signal is an integrated cellular response [16]. Thus,
the use of the DMR signal as an alternative readout for
receptor activation is advantageous. Since many cell sign-
aling events involve significant redistribution of cellular
matters, the biosensor-based assays may find broad appli-
cability in many different types of targets including
GPCRs [16,18,34], EGFR [17] and ion channels (unpub-
lished data). In A431 cells, we recently have identified
three classes of DMR signals induced by panels of GPCR
agonists targeting several endogenous receptors, each of
which was correlated well with the activation of a class of
GPCRs, depending on the G protein with which the recep-
tor is coupled (i.e., Gq, Gs and Gi).
Because of the short penetration depth of the evanescent
wave of the present biosensor, only cellular events occur-
ring within the detection zone of the cell layer contribute
to ligand-induced DMR signals. Although ligand-induced
receptor activation may lead to an array of signaling path-
ways or events [16-18], only signaling events having sig-
nificant redistribution of cellular matters could be
detected. Recently we have developed a mathematical
model for the DMR signals mediated by Gq-coupled
receptors [16]. We also have shown that a GPCR ligand-
induced DMR signal primarily consists of three compo-
nents: trafficking of intracellular targets to the activated
receptors and subsequently receptor internalization [16],
changes in cell adhesion degree [35], and cytoskeletal
remodelling which is at the crossroad of the receptor acti-
vation to downstream signaling events [[18], unpublished
data].
Here we examined the signaling of endogenous PARs in
A431. Among PAR agonists examined, only PAR1 and
PAR2 agonists resulted in significant Ca2+ mobilization
and Gq-type DMR signals. This result is consistent with the
fact that only PAR1 and PAR2 are endogenously expressed
in A431, and both receptors elicit Gq signaling. The DMR
signals induced by all PAR1  and PAR2  agonists share
almost identical dynamics, except of the signaling ampli-
tudes (Fig. 2a). The overall dynamics – an initial rapid P-
DMR event followed by a relatively slow N-DMR event –
is also similar to those mediated through the activation of
other endogenous Gq-coupled receptors in A431 cells
[[17,34]; unpublished data]. Our recent theoretical analy-
sis suggests that for Gq-coupled receptors, the P-DMR is
primarily resulted from the recruitment of intracellular
targets to the activated receptors at the cell membrane,BMC Cell Biology 2007, 8:24 http://www.biomedcentral.com/1471-2121/8/24
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while the receptor internalization is a major contributor
to the N-DMR event [16]. Furthermore, the PAR agonist-
induced DMR signals also share similarity with the Ca2+
ionophore A23187-induced DMR signal (Fig. 7c), sug-
gesting that the DMR signals of PAR agonists obtained are
mainly downstream of Ca2+ pathway. In addition, com-
pared to Ca2+ mobilization signals, the less pronounced
difference in the maximal DMR responses of different PAR
agonists also indicates that the DMR signals are down-
stream of Ca2+ mobilization. It is a recent finding that in
many cases an agonist-induced maximal response, a
measure of agonist efficacy, is dependent on the cellular
events measured. This is because GPCR signaling typically
proceeds through a series of amplification steps. As a
result, the closer to the receptor activation step the cellular
event measured is, the bigger difference the agonist effi-
cacy might be [32]. Together, these results suggest that the
DMR signals of PAR agonists are primarily resulted from
Gq signaling, although one cannot rule out the contribu-
tions of other signaling pathways to the overall DMR sig-
nal.
Nonetheless, similar to Ca2+ mobilization, the ligand-
induced DMR signals are not only dependent on and sat-
urable to ligand concentrations (Fig. 1), but also show
classical desensitization patterns upon repeated agonist
stimulation (Fig. 5), suggesting that the DMR signal can
serve as a novel readout for monitoring receptor activa-
tion. Interestingly, the two PAR2-specific agonists SLIGRL-
amide and SLIGKV-amide-induced maximal responses,
measured using both Ca2+ flux and MRCAT assays, were
significantly different (Fig. 2b). Such difference may be
due to the functional selectivity of G protein signaling by
soluble PAR agonists [33].
Three lines of evidences suggest that there are functional
interactions between PAR1  and PAR2  in A431. First,
among PAR1,2 agonists examined, trypsin resulted in the
highest Ca2+ mobilization, while SFLLR-amide led to an
intermediate Ca2+ mobilization. Similar trend was also
observed in their DMR signals (Fig. 2). Co-stimulation
with SFLLR-amide and SLIGKV led to Ca2+ mobilization
or a DMR signal that is at the level similar to that induced
by trypsin alone. These results suggest that: (i) the soluble
PAR1 ligand SFLLR-amide may partially activate PAR2, and
(ii) trypsin may transactivate PAR1  through unknown
mechanism(s). Secondly, the desensitization patterns, as
examined using repeated stimulation with various combi-
nations of PAR agonists, also support the functional inter-
actions between PAR1 and PAR2. The trypsin-treated cells
lost their responsiveness to either PAR agonist examined,
but not to bradykinin, while the thrombin-treated cells
still respond to trypsin. Thirdly, a PAR1 partial agonist
YFLLRNP-amide can attenuate the DMR signals induced
by thrombin or SFLLR-amide, but not SLIGKV-amide. At
729 μM YFLLRNP-amide totally blocked the DMR signal
induced by thrombin, but only partially attenuated those
induced by either SFLLR-amide or trypsin. Collectively,
these results suggest that both SFLLR-amide and trypsin
might activate both receptors.
Although it appears that both receptors elicit Gq signaling
in A431, there is distinct difference in the kinetics of
receptor re-sensitization. The prolonged stimulation (~1
hr) with trypsin resulted in complete desensitization of
cells to sequential stimulation with thrombin, but partial
desensitization to SFLLR-amide, SLIGKV-amide or SLI-
GRL-amide (Fig. 5). On the other hand, the cells still
respond to trypsin, after pre-stimulation with thrombin,
SFLLR-amide, SLIGKV-amide, or SLIGRL-amide. These
suggest that PAR2 resensitizes much faster than PAR1. It is
known that receptor proteolysis and phosphorylation reg-
ulate the activities of PARs through receptor internaliza-
tion and the inhibition of intracellular signal transduction
[9,36,37]. Depending on the cellular context, the recovery
of functional receptors at the cell surface could take from
tens of minutes to hours [38,39].
The almost identical sensitivity of both trypsin- and
thrombin-induced Ca2+  mobilization to cholesterol
removal suggests that the cell surface cholesterol level
plays an equally important role in regulating the ampli-
tudes of Ca2+ mobilization induced by the activation of
both PAR1 and PAR2. It is known that cholesterol extrac-
tion leads to the loss of compartmentalization of PtdIns
4,5-P2, and Gq, two important molecules for PAR signal-
ing [40,41]. The suppression of Ca2+mobilization by cho-
lesterol depletion might be a direct result of
delocalization of PtdIns and Gq.
Interestingly, the DMR signals induced by trypsin or
thrombin exhibited different dependency on the concen-
tration of mβCD in solution. The pre-treatment of cells
with mβCD but not its inactive analog αCD attenuated
PAR signaling including Ca2+ mobilization and DMR sig-
nals induced by thrombin or trypsin. The partial inhibi-
tory effect of EGF pre-treatment suggests that the
transactivation of EGFR by cholesterol depletion may
attenuate, directly or indirectly, the N-DMR event medi-
ated by thrombin or trypsin (Fig. 8b and 8c). Since the
DMR signal is an integrated cellular response, it is very
sensitive to the cellular background [17,18]. The activa-
tion of EGFR directly by EGF, or indirectly by cholesterol
depletion, could alter the cellular background, thus indi-
rectly impairing the N-DMR event induced by both PAR
agonists. Alternatively, the EGFR activation or transactiva-
tion could lead to signaling pathway(s) crosstalking with
GPCR signaling.BMC Cell Biology 2007, 8:24 http://www.biomedcentral.com/1471-2121/8/24
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For PAR1, the cell surface cholesterol level seems equally
regulate both Ca2+ mobilization and DMR signal, because
both types of cellular responses induced by thrombin
exhibited the same sensitivity to mβCD concentration in
solution. Conversely, for PAR2 the cell surface cholesterol
level appears regulate Ca2+ mobilization and DMR signal
differently. Such a difference in sensitivity to mβCD con-
centration between the trypsin- and thrombin-induced
DMR signals suggest that two receptors may involve dif-
ferent cellular mechanism(s) or signaling network interac-
tions.
Conclusion
The signaling of endogenous PAR1 and PAR2 in A431 was
studied using non-invasive and manipulation-free optical
biosensor. The biosensor-manifested DMR signals follow
classical receptor biology. Similar to Ca2+ mobilization,
the DMR signals are saturable to ligand concentrations;
exhibit comparable desensitization patterns in response
to repeated stimulation with various combinations of
agonists; and are sensitive to cell surface cholesterol level.
More significantly, data analysis suggests that the biosen-
sor differentiates the signaling of PAR1 and PAR2 in A431
under physiologically relevant conditions.
Methods
Reagents
Thrombin, trypsin, methyl-β-cyclodextrin (mβCD),
A23187, AG1478, α-cyclodextrin (αCD), and epidermal
growth factor (EGF) were purchased from Sigma Chemi-
cal Co. (St. Louis, MO). Fluo-3 was obtained from Molec-
ular Probes (Eugene, OR). SFLLR-amide, SLIGKV-amide,
SLIGRL-amide, bradykinin, TFRGAP, GYPGQV, and YFLL-
RNP-amide were obtained from Bachem (King of Prussia,
PA). All compounds were used as received. Corning®
Epic™ 96well biosensor microplates were obtained from
Corning Inc (Corning, NY), and cleaned by exposure to
high intensity UV light (UVO-cleaner, Jelight Company
Inc., Laguna Hills, CA) for 6 minutes before use.
Cell culture
Human epidermoid carcinoma A431 cells (American
Type Cell Culture) were grown in Dulbecco's modified
Eagle's medium (DMEM) supplemented with 10% fetal
bovine serum (FBS), 4.5 g/liter glucose, 2 mM glutamine,
and antibiotics. ~5 × 104 cells at passage 3 to 8 suspended
in 200 μl the DMEM medium containing 10% FBS were
placed in each well of a 96well microplate, and were cul-
tured at 37°C under air/5% CO2 for ~2 days, followed by
~20 hr starvation through continuously culturing in the
serum-free DMEM.
Fluo-3 Ca2+ mobilization assay
Cells were grown in Costar™ 96well clear cell culture
microplates. After starvation, the cells were washed with
1× HBSS (1× regular Hank's balanced salt solution, 20
mM HEPES buffer, pH 7.0) in the presence of 2.5 mM
probenicid, and labeled in the same buffer containing 4
μM Fluo-3 for 1 hour at room temperature. The cells were
then washed twice with buffer, maintained with 100 μl 1×
HBSS containing 2.5 mM probenicid. The assay was initi-
ated by transferring 50 μl PAR agonist solution to the cell
plate, and calcium signal was recorded over 6 minutes
with a 6 sec interval using HTS7000 BioAssay Reader
(PerkinElmer Life Science, Boston, MA). The fluorescent
intensity before stimulation was recorded and used as a
baseline. The percentage increase in fluorescence intensity
after stimulation, relative to the baseline fluorescence, was
analyzed and used directly as a measure for the increase of
intracellular Ca2+ level induced by PAR agonists.
Optical biosensor measurements
Corning® Epic™ angular interrogation system with trans-
verse magnetic or p-polarized TM0 mode was used for all
studies. The detailed instrumental setup and assay proto-
cols had been previously described [16-18]. Briefly, all
compound solutions were prepared using 1 × HBSS con-
taining minimal amount of dimethyl sulfoxide, while the
starved cells were washed and maintained with 100 μl the
serum-free DMEM. The cells were then treated with 50 μl
1 × HBSS buffered solution in the absence and presence of
a compound, followed by stimulation with ligand solu-
tions. The cellular responses were monitored in real time
throughout the assays.
For functional recovery after cholesterol removal with
mβCD, the quiescent A431 cells were treated with 5 mM
mβCD for 15 minutes to ensure the removal of cell surface
cholesterol content, followed by washing the treated cells
three times with the medium only. The cells were then
maintained with 100 μl the medium, and placed into the
optical systems. After incubation for 15 minutes to allow
cells reaching reasonably steady state, a 100 μl solution of
thrombin at 80 unit/ml was added to each well at specific
time. The optical responses were recorded throughout the
assays.
Statistical analysis
Unless specifically mentioned, three replicates were car-
ried out for each measurement or each compound. The
standard deviation was derived from these measurements
(n = 3). The assay coefficient of variation was found to be
typically less than 10%. All dose-dependent responses
were analyzed using non-linear regression method with
the Prism software (Graph Pad).
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